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Abstract
The aim of the present investigation is to produce rapidly disintegrating laminar extrudates for 
delivering ibuprofen in the mouth of paediatric patients. This laminar shape is particularly 
convenient for drug delivering in the mouth and can be easily cut in cut in different sizes allowing 
for a convenient adjustment of the drug dose depending on the age of the patient. Due to the fact 
that in paediatric formulations, the selection of the excipients is always a challenging issue and the 
reduction of their amount is always highly desirable, in this study to select the most appropriate 
composition to achieve a rapid disintegration and simultaneously permit a high amount of 
ibuprofen in the system, an experimental design for mixtures was employed and the disintegration 
time in simulated saliva was used as experimental response. In addition, after solid state analyses to 
check possible insurgence of drug-excipients interactions, laminar extrudates were characterised in 
terms of mechanical properties and in vitro dissolution performances. Extrudates with the desired 
uniform laminar shape, constant thickness (2 mm) and a very high content of drug (82% wt) were 
produced. These products exhibited a short disintegration time. The dose for a patient of 6-12 years 
corresponded to a length of extrudate between 1-1.5 cm, perfectly compatible with a formulation 
orodispersible thin laminar extrudate intended for a paediatric patient (Figure 1).
Keywords: Paediatric formulation; Flexible formulation; Orodipersible formulation; Excipients; 
Disintegration
Introduction
The wet extrusion technology has long been known, but usually it represents an intermediate step 
which precedes the spheronization [1]. In this case it has been employed to prepare by wet extrusion 
an orodispersible ibuprofen paediatric formulation for patients aged 6-12 years, containing a dose 
of active ingredient of 100mg. These thin laminar extrudates are requested to accomplish various 
demands at the same time, such as rapid dispersion in the mouth, loading a dose of active principle 
in a piece of extruded compatible to a paediatric administration, the use of auxiliary components 
permitted for paediatric useand finally a high content of active principle and little amount of 
excipients (thus having less chance of toxicities or intolerance in young consumers) [2-5]. In this 
context, the extrusion process was chosen because it has the great advantage, compared to other 
technologies, to allow loading of high quantities of active principle. Moreover, the laminar shape 
of the extrusions that can be obtained in a single step from a rectangular die could allow an easy 
modulation of the ibuprofen dose depending on the age and weight of the patient simply varying the 
length of the extrudate. Further a laminar orodispersible extrudate have minimal impact on lifestyle 
and a reliable and convenient administration, as requested for an ideal formulation for children 
[6]. Not being commercially available orodipersibles formulation prepared by wet extrusion, as a 
parameter of comparison, in all steps of research, a marketed formulation Nurofen® comprimés 
fondants 200 mg, oro-dispersible tablets available on the market in Belgium, was used. Further, 
due to the lack of characterizations for this innovative dosage form, alternative analyses used for 
the evaluation of films and orodispersible tablets or sublingual tablets were adapted and proposed.
Materials and Methods
Materials
Ibuprofen EP (IBU) (Acef), Crospovidone (Kollidon CL, Basf)- PVP-CL, Povidone (Kollidon, 
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BASF)-PVP, Microcrystalline cellulose (AvicelPh 101, FMC)- MCC, 
Aspartame - E 951(Acef), Polisorbate 80 (Montanox 80, Seppic) 
-E433were used. Nurofen® comprimés fondants -200 mg (Reckitt 
Benckiser Healthcare- commercialized in Belgium) were used for 
comparison purposes as solid oro-dipersibile dosage for m containing 
ibuprofen. This formulation is indicated for children over the age 
of12 years and for salein Belgium. Nurofen® comprimés fondants 200 
mg contains in addition to 200 mg of active ingredient the following 
inactive ingredients: ethyl cellulose, precipitated silica, hypromellose, 
mannitol, aspartame (E951), Croscarmellose sodium, magnesium 
stearate, flavor (lemonor other). The total weight of the tablet is 700 
mg, thus excipients represent 71.4% by weight.
Methods
Powder mixture composition and experimental design: The 
mixtures to be subjected to wet extrusion process were designed 
using experimental design for mixtures [7], using the soft ware 
NEMRODW [8]. To reduce systematic errors, the extrusion tests 
were performedinrandomorder. The mixture subjected to extrusion 
consists of five powder components (drug, microcrystalline cellulose, 
crospovidone¸ povidone) of which the active ingredient and the 
sweetener, which together accounted for 89% (w/w), were maintained 
in a constant quantity, while the proportions of the remaining three 
(together accounting 11% w/w) were varied to obtains even different 
pseudo-mixtures. The limits of each component in the pseudo-
mixtures were defined during the preliminary trials obtaining 
the following values: for microcrystalline cellulose  0≤X1≤3, for 
crospovidone 3≤X2≤6, for povidone 3≤X3≤6 (%w/win the mixture). 
For the palatability of the final formulation as partame was included 
in the fixed amount of 7% in the different mixtures with the rationale 
that for every 100 mg of ibuprofen are required 8.5 mg of aspartame 
for palatability of the final formulation, as in the marketed formulation 
chosen as a comparison (Nurofen® comprimés fondants 200 mg). The 
experimental matrix is given in Table 1 and the experimental design 
space is depicted in Figure 2.
Wet Masses Preparation
One hundred batches of powders (active ingredient, sweetener 
and the three auxiliary excipients) were dry blended in a food mixer 
for 10 runs including 30 sec (mixing) and 1 minute (repose). The 
composition of the mixtures was in accordance to the proportions 
reported in Table 1, obtaining seven pseudo-mixtures. The mixtures 
were then wetted with 32% (w/w) of deionized water added with 1% of 
wetting agent while mixing. The kneading was carried out for further 
10 minutes. The level of wetting was defined during the experimental 
tests. Evaluation of the content uniformity of the final extrudate 
established that the mixing had been successful. As wetting agent 
polysorbate 80 was selected from excipients acceptable in pediatric 
formulations and used at a low percentage, in consideration of the 
objective of reducing the toxicity of the final dosage form intended for 
a pediatric use. For clarity, Table 2 shows the composition of the final 
7 mixtures. The dry mixtures were wetted with 32% demineralized 
water plus 1 % of polysorbate 80 (w/w). Once produced, the mixtures 
were packaged in sealed bags and allowed to equilibrate for 24 h at 
room temperature, away from light and heat sources.
Extrusion Procedure 
The laminar extrudates were prepared using a vertical lab scale 
ram extruder (Thalassia®, Trieste, Italy) described into details in a 
previous work [9]. Briefly, the movement of the stainless steel ram in 
this extruder is promoted by an oleo dynamic cylinder driven by an 
electric pump (max pressure 150 bar). The cylindrical nickel plated 
brass barrel, acting as a powder reservoir, has a capacity of 66 cm3 
and an internal diameter of 25 mm. The die attached at the end of the 
barrel can be changed on demand: in this case a die with flat entry 
and rectangular shape (2 mm x 8 mm cross section) was used. The 
extruder chamber, thermo stated at 25°C, was loaded with 50 g of 
each mixture. The mass was forced through the die using a constant 
ram velocity. The obtained laminar extrudates were collected during 
the steady-state flow stage and deposited in trays covered with 
baking paper, and finally dried (in static oven) at 35°C until constant 
weight was achieved (4h).These drying parameters, chosen based on 
previous experience and according to the data of literature [10] did 
not influence the solid state characteristics of the blends, as assessed 
by DSC and PXRD analyses. Then, the laminar extrudates were sliced 
up in unities of length (1.5 cm) suitable to have 100 mg drug content 
and stored in well-closed bags for 7 days before characterizations.
Experimental matrix 
Exp. Random sequence MCCX1 (%)
PVP-CL
X2 (%)
PVP
X3 (%)
1 2 0 50 50
2 6 13,6 43,2 43,2
3 1 27,2 36,4 36,4
4 4 17,3 28,2 54,5
5 3 11 54,5 34,5
6 7 17,3 54,5 28,2
7 5 11 34,5 54,5
Table 1: Pseudo mixture Experimental matrix.
Figure 1: Convenient adjustment of the drug dose depending on the age of 
the patient.
Figure 2: Experimental design space (A) and graphical representation of 
mixture components’ effects on the response Y (B).
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Wettability Measurements
In order to assess the effect of the addition of surfactant on the 
Wettability of the active substance ibuprofen, which represents 82% 
w/w of the formulations and therefore is by far the predominant 
component, the contact angle was measured. This evaluation was 
carried out according to the drop method on compressed non-
disintegrating disks, using deionized water as a wetting liquid. Two 
types of compacts were subjected to this test: tablets of ibuprofen 
wetted by a) deionized water (32% w/w) and b) deionized water (32% 
w/w) plus 1% of polysorbate 80. Disks were prepared compressing 
the mixtures in a manual press Perkin Elmer, imparting a force of 5 
tons for 1 minute. After compression, the tablets were dried at 40°C 
using the same procedure as the extrudates. The flat tablets produced 
were then analyzed with the Drop Shape Analysis System (Krüss DSA 
30), using as a wetting solution 5 ml of purified water. The contact 
angle measurement, performed in triplicate was performed after 10 
seconds.
Characterisations of the Laminar Extrudates
Solid state analyses
Thermal analyses were conducted using a differential scanning 
calorimeter DSC Mettler TA 4000 (Greifensee, Switzerland) 
connected to a cell Mettler DSC20 calorimeter, equipped software 
STARe software version 9.30. The analysis was conducted on 
fragments of extruded, on the raw materials and physical mixtures 
prepared in the same weight ratios of the systems obtained by 
extrusion. The samples were subjected to a dynamic heating speed 
of 10°C / min in a temperature range between 25 and 200°C in air 
atmosphere. Furthermore, a STOE D500 diffractometer (Siemens, 
Monaco) was employed, analysing samples in the range of angle 
2θ from 5 to 35 ° 2θ with a step of 0.05 degrees of 2θ, and counting 
time of 2 seconds. The current used was 20 mA and the voltage of 
40 kV. The following samples were analysed: raw materials, laminar 
extrudates previously ground in an agate mortar, and corresponding 
physical mixtures.
Thickness and breaking load measurements
In order to simulate the pressure exerted on the formulation by 
the tongue, the tensile strength of laminar extruded was determined 
in transversal direction by using a Hardness Tester Model TBH 
30 Erweka (Heusenstamm, Germany). For each formulation 10 
extruded samples were analysed. At the same test, 10 reference 
commercial tablets were analysed, impressing the breaking load again 
in transversal direction of the tablet. The same device was used to 
measure extrudate and tablet thickness (mean ± SD, n=10).
Disintegration Tests
The disintegration test (observed response Y) was conducted in 
a modified USP disintegration test, using 10 ml of pH 6.8 buffer as a 
medium (simulated saliva), since the classical EP method (employing 
900 mL of disaggregation medium) is not adequate to simulate the 
mouth cavity environment and to test orodispersibleformulations. In 
short, the method used consisted of a beaker glass of 25 ml containing 
5 ml of phosphate buffer, subjected to the same agitation and heating 
(temperature-controlled bath at 37°C) of the USP disintegrating 
apparatus (Erweka ZT3, Eusenstamm, Germany). The extrudates 
were observed during the analyses, and their time of disaggregation 
was counted using a stopwatch. The analysis was repeated six times 
for each sample, always using as a comparison specialty commercial 
Nurofen® comprimés fondants 200 mg.
Attempts to impart the extruded during the disintegration test 
at a pressure similar to that exerted by the tongue were unsuccessful, 
since the calibrated weight (100 g) cylinder, positioned over the 
laminar extrudate, excluded the monitoring of the disintegration 
time.
Stimulated Wetting Test
To evaluate the ability of hydration over time of the extruded 
samples, simulating their behavior when in direct contact with saliva, 
extruded samples of about 1-1.5 cm (equal to 100 mg of ibuprofen) 
from each mixture were cut, carefully weighed, and subjected to the 
method reported in the literature [11-13]. In short, the fragments 
of extruded were placed in a tray covered by a layer of absorbent 
paper (size 11x7 cm) impregnated with phosphate buffer (acting 
as a tongue), and on the top covered with two layers of absorbent 
paper impregnated of phosphate buffer (simulating the palate). At 
fixed times (15, 30, 45, 60, 75, 90, 105, 120 seconds) fragments were 
collected and weighed by calculating the percentage of hydration at 
various times with the following formula (eq.1):
  (eq. 1)
For every time point the three samples of each mixture were 
tested.
In vitro Drug Dissolution
The in vitro ibuprofen dissolution studies were performed using 
the method proposed for sublingual tablets by Rachid et al. [12]. The 
dissolution medium consisted in 5 ml of pH 6.8 phosphate buffer 
(prepared with 4.33 g of K2HPO4 and 3.39 g KH2PO4), thermostated at 
37° C. Samples of extruded containing 100 mg of ibuprofen (suitable 
dose for children aged 6-12 years) and approximately 1- 1.5 cm in 
length, were placed on the filter (porosity 0.45 uM) and covered with 
buffer solution. At each time point, the vacuum pump (KNF Laboport 
- Neueberg) was activated to allow the removal (in the tube below 
the vacuum filter) of the solution containing the drug dissolved. The 
times selected, by virtue of the presence of orodispersible formulation 
in the mouth, were the following: 15, 30, 45, 60, 90, 120 seconds (6 
time points). The analysis was conducted in threefold repetition: for 
each distinct time point 3pieces of laminar extrudates of the same 
mixture were taken. The dissolution medium was then filtered 
and assayed spectrophotometrically (after appropriate dilution 
with phosphate buffer thermostated at 37°C, if necessary) at 223 
nm (Spettrofotometer Biochrom Libra S12, Cambridge, UK). For 
comparison, dosage units of oro-dispersible Nurofen® comprimés 
Table 2: Composition of the wet masses (100 g powder plus 32 g water and 1 
g surfactant).
Components
in variable amounts(*)
Component
in fixed amounts
Exp. MCC PVP-CL PVP IBU Aspartame H20 Surfactant
1 0 5.5 5.5 82 7 32 1
2 1 4.7 4.7 82 7 32 1
3 3 4 4 82 7 32 1
4 1.9 3.1 6 82 7 32 1
5 1.2 6 3.8 82 7 32 1
6 1.9 6 3.1 82 7 32 1
7 1.2 3.8 6 82 7 32 1
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fondants 200 mg were therefore divided into halves (to get the same 
dose of active ingredient) and subjected to the same analysis. Given 
the small number of samples (3 repetitions for each time point) 
statistical analysis of the data were not carried out.
Results and Discussion
The objective of this study was to obtain by wet extrusion an 
orodispersible dosage form containing ibuprofen intended to patients 
aged between 6 and 12 years. Not being orodispersible extrudates 
available on the market, as a comparison parameter, in every step 
of the research, the marketed formulation Nurofen® comprimés 
fondants 200 mg (from now on “reference”) was used.
The extrusion was preferred over other techniques because 
innovative and because it allows to incorporate high amounts of 
active principle up to a maximum of 90% in the final product [1]. 
Furthermore, this technology enables to obtain, through appropriate 
selection of the die, a shape suitable to administration in the mouth. 
In this research it was chosen a rectangular die allowing to obtain a 
thin laminar shape of extrudates, having thickness of 2 mm, width of 
8 mm and length that can be chosen according to the desired dose 
(and, in this case, to the patient's age). The small thickness of the 
extrudatespresumably consents an easy dispersion in the mouth. In 
order to reduce as much as possible the amount of other ingredients 
in the final dosage form, thus limiting the possibility of adverse 
reactions by the same auxiliary components, it would be highly 
desired that such formulations provide a high drug loading. 
Furthermore, due to the goal of rapid dispersions in the mouth, such 
formulations must contemplate the presence of disintegrating 
excipients that favour the disintegration of the solid form in the 
mouth cavity. Finally, in this preliminary study, for the palatability of 
the final formulation, being an orodipersible formulation and 
ibuprofen a well- known bad tasting drug [14-16], 
Aspartamewasincluded in the fixed amount of 7% in the different 
mixtures with the rationale that for every 100 mg of ibuprofen is 
required 8.5 mg of aspartame, as in the marketed formulation chosen 
as a comparison. In view of its well-known toxicity [17] the idea is to 
replace it in a subesquent study. First preliminary tests were carried 
out in order to define the optimal quantity and composition of the 
binder solution, usually ranging about 32-40% w/w [1]. The powder 
masses were composed of ibuprofen and microcrystalline cellulose, 
the most classical diluent/binder for wet extrusion [1]. During such 
preliminary tests it was noted that with a 37-40% water content, the 
masses showed insufficient consistency and irregular shape as they 
flowed out of the die at very low pressures, while masses containing 
less than 32% water were not sufficiently plastic to be extruded (the 
extrusion process required higher pressures than those permitted 
from the apparatus) or togive origin to regular extrudates (e.g. 
sharkskin defects, surface cracks or fractures). Then several 
disintegrants, such as cross linked cross carmellose sodium (AcdiSol® 
FMC, Bruxelles, B), Soy polysaccharides (Emcosoy® STS IP, JRS 
Pharma Rosenberg, DE), sodium starch glicolate (Explotab®, JRS 
Pharma, Rosenberg, DE) and crospovidone were tested in association 
with high percentages of ibuprofen (superior to 80%). In the selection 
of such excipients the disintegrant ability and attitude to wet extrusion 
process of classical synthetic excipients (such as crospovidone) was 
compared with that of other ingredients of natural or semi-synthetic 
origin, that are commonly preferred in formulations for children by 
paediatricians and from the market. At the end of such screening, 
however, only crospovidone resulted capable of forming extrudates 
having regular shape and smooth surface, while permitting a rapid 
disintegration in water. During preliminary trials the following limits 
of the 3 above mentioned excipients in the pseudo-mixtures were 
defined: for microcrystalline cellulose 0≤X1≤3, for crospovidone 
3≤X2≤6, for povidone 3≤X3≤6 (% w/win the mixture). It is interesting 
to note that the presence of microcrystalline cellulose was found not 
mandatory for the extrusion process, opening the possibility to 
further reduce the number of included excipients, and to prevent 
delay of disintegration due to the presence of microcrystalline 
cellulose. Also during preliminary trials, the addition of 1% surfactant 
in the binder solution was found to be necessary to achieve a rapidly 
disintegrating product. This was due to the fact that ibuprofen, which 
represents 82% w/w of the formulations and therefore is by far the 
predominant component, is a hydrophobic powder [18]. The addition 
of 1% polysorbatein the binder solution determined a remarkable 
reduction of mean contact angle: pure ibuprofen was 77.05±7.09°, 
whilst after addition of 1% polisorbate 80 the value diminished to 
Figure 3: PXRD pattern of a laminar extrudate (sample 7), compared to 
pure drug, corresponding physical mixture (P.M.) and the physical mixture 
subjected to isothermal conditions mimicking drying procedure (P.M. ISO).
Table 3: Characterization results of the laminar extrudates and reference formulation.
Sample 
Thickness
(mm) 
(mean ± SD, n= 10)
Hardness
(N)
(n= 10)
Percent drug content
(mean ± SD, n= 3)
Loading efficiency (%)
(mean ± SD, n = 3)
Disintegration time
(sec)
(mean±SD, n = 6)
1 1.85 ± 0.18 <10 N 89.3 ± 5.5 111.3 ± 3.0 115 ± 21 
2 1.9± 0.13 <10 N 86.02 ± 6.0 113 ± 7.0 73 ± 17 
3 2.03±0.16 <10 N 93.9 ± 7.0 114.5 ± 8.2 187 ± 24 
4 1.9± 0.13 <10 N 96.7 ± 4.0 118 ± 4.5 85 ± 8 
5 2.3±0.12 <10 N 91 ± 8.4 111 ± 10.3 88 ± 10 
6 1.93±0.13 <10 N 86.6 ± 5.0 95.3 ± 4.0 32 ± 7 
7 2.19±0.16 <10 N 95.5 ± 1.3 116.5 ± 1.6 21 ± 4 
Reference formulation <10 N n.d. n.d. 39 ± 12 
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51.55±5.35 (mean± SD, n = 3). Extrudates with the desired uniform 
laminar shape, constant thickness (2 mm) and a very high content of 
drug (82% wt) were produced with all the compositions (Table 3). 
The thickness varies very little from the dimensions of the die, 
demonstrating the absence of phenomena of expansion after the exit 
from the die or deformation while drying or over storage. The 
recorded values are affected by the composition of the mixture and 
are reproducible within batches with the same composition. The 
dimensions are compatible with the objective of administration in the 
mouth and promising for the purposes of dispersion in the mouth 
itself. The dose for a patient of 6-12 years (100 mg) corresponded to a 
length of extrudate between 1-1.5 cm, perfectly compatible with a 
formulation orodispersible thin laminar extrudate intended for a 
paediatric patient. At the end of the selection of the excipients, the 
physical compatibility between the drug and excipients was check for 
any interactions that could occur between components during the 
various processing steps. Extruded samples were analysed by DSC 
and PXRD, in comparison with the same physical mixtures having 
ratios by weight active principle/excipients and with the individual 
raw materials. Again, due to comparative purposes the physical 
mixture was subjected to an isothermal heating simulating drying 
conditions and then analysed by DSC and PXRD. The results of the 
PXRD (Figure 3) and DSC analyses (data not shown for brevity) 
agreed to attest the absence of interactions and significant changes in 
the solid state of the active ingredient by simply mixing, or as a result 
of the process drying or extrusion. As it can be seen from disintegration 
tests, the addition of surfactant permitted to the laminar system 
(having a very high content of drug) to be homogeneously wetted, 
thus reaching crospovidone particles and allowing for rapid 
disintegration. The most rapid systems disintegrated in less than 30 
sec. The laminar extrudates disintegrated with different disintegration 
times, depending on their composition, and the disintegration time 
was in some cases comparable to that of the marketed formulation 
(around 30 sec). This result is particularly significant when taking 
into account that these extrudates contain a very high amount of 
active ingredient, whereas the reference contains the 28.6% of drug. 
The effect of varying percentage of individual components in mixtures 
on the disintegration time in pH 6.8 buffer were evaluated graphically 
by use of the program NEMRODW, considering the disintegration 
time as experimental response (Figure 2). Disintegration time 
decreased as the amount of crospovidone increased, and as the 
amount of cellulose diminished. To go into more details, from the 
graphical evaluation of the effect on the disintegration time of the 
percentage of the individual components on mixtures wetted with 1% 
polysorbate 80 the following considerations can be drawn: the higher 
the content of povidone and crospovidone in mixtures, extrudates 
break up in less time, while increasing the proportion of 
microcrystalline cellulose in mixtures there has been a slowdown in 
disintegration, as expected from a diluent/binder insoluble in water 
[19]. Looking at the slope of the three lines, each corresponding to the 
percentage of a component, a greater influence of the percentage of 
microcrystalline cellulose than the other two excipients may be 
observed. The composition of the extruded demonstrating the best 
disintegration time in the group was: in addition to the fixed amounts 
of 82% of API and 7% of aspartame, 6% of crospovidone (limit of 
experimental plan) and1.9% of microcrystalline cellulose and 3.1% of 
PVP. By assessing the disintegration time in light of the other 
performed characterizations (results reported in Table 3), it can be 
seen how the disintegration is not dependent on the thickness nor the 
hardness of the extrudates. No correlation between the above 
properties and disintegration was noticed. In fact, while the 
disintegration varies significantly from sample to sample, the 
thickness and the breaking load (less than 10 N in all cases) are quite 
similar. The composition of the extrudates appears therefore primarily 
responsible for the different performance. In order to assess the 
ability of such dosage forms hydrate when in contact with small 
amounts of water, a method proposed in the literature and in the case 
of laminar extruded [11], sublingual [12] and orodispersible 
preparations [13] was used. The results of this test are reported in 
Figure 4, where it can be observed thatwater absorption varies 
between 3 and 25%. The samples that showed a greater absorption of 
water corresponded to samples with lower disintegration time. Such 
amount of water absorbed (3-25%) are perfectly compatible with the 
small amounts of hydrophilic colloids, able to swell and absorb water 
present in the extruded and are always able to determine the 
fragmentation extrudate in the mouth. As expected, the commercial 
sample containing rather large amounts of hydrophilic agents, e.g. 
croscarmellose sodium, absorbed much greater amounts of water. 
The correspondence between simulated wetting time and 
disintegration time proved that this was due to the time required for 
water to diffuse through the whole extrudate, rather than the hardness 
of the extrudates, that was found in all case very scarce (Table 3). 
Finally, in order to evaluate the release of active ingredient from the 
formulation in the short time of stay in the mouth, and then predict 
whether the active ingredient can be dissolved in the saliva and be 
available for absorption, in vitro dissolution test was carried out. 
Although it was not a goal of the research, the absorption of a certain 
percentage of the dose of active principle before swallowing would 
allow a quick pharmacological onset and would partly bypass the 
gastro-intestinal tract. In addition, knowledge of drug dissolution in 
Figure 4: Simulated wetting test profiles of laminar extrudates and reference 
formulation.
Figure 5: In vitro dissolution profiles of laminar extrudate (formulation N° 7) 
(red) and reference formulation (black). 
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the saliva is an important finding to design the subsequent study of 
taste-masking formulation of the extrudate. Sample 7 showing the 
shortest disintegration time in each set was selected cut in fragments 
having a content of 100 mg of active and subjected to in vitro 
dissolution test according to the method proposed by Rachid et al. 
[12]. Reference tablets, divided in halves (to have the same content of 
active principle), were also tested in analogous conditions. The results 
(Figure 5) proved that a certain amount of ibuprofen (about 5%) is 
released, and hence available for absorption, from the extrudates in 
less than 2 minutes (average time of permanence of a orodispersible 
formulation in the mouth) thanks to the hydrophilic components of 
the formulation and the presence of the surfactant, despite the poor 
solubility of the active principle.
Conclusion
Rapidly–disintegrating laminar extrudates, easy to be cut in 
different lengths allowing for a convenient adjustment of the drug 
dose, can be a viable and age appropriate formulation to deliver 
ibuprofen in children. These systems offer several advantages, 
including the easy administration without need of water, the use of 
very little amounts of excipients (18% by wt) per each drug dose, the 
easy dose adjustment depending on the age of the patient.
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